GSK Poster Hub
WEBThis Congress Poster Site was created to enable delegates attending congresses to access GSK posters. All posters and the studies they report were supported by GSK; all posters are related to abstracts that were independently peer-reviewed for …
GSK Poster Hub
WEBApr 15, 2021 · GSK Poster Hub. American Association for Cancer Research (AACR) 2021. Virtual Meeting, Week 1, April 10–15, 2021. Index of GSK posters at AACR 2021. Please click on the titles below to view and download the posters. Thursday 15 April 2021.
GSK to present updates on its industry-leading infectious disease ...
WEBOct 12, 2022 · GSK plc (LSE/NYSE: GSK) will share updates on its industry-leading infectious disease pipeline and portfolio with 33 abstracts accepted for the Infectious Disease Society of America’s IDWeek 2022 annual meeting in Washington, DC, US from 19-23 October 2022.
Full List of GSKs Scientific Presentations | GSK US
WEBSafety and Clinical Activity of Belantamab Mafodotin plus Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma: The Phase 1/2, prospective, open-label, BelaRd study. Terpos E. Poster Presentation.
Scientific Meetings | GSK US Medical Affairs
WEBView conference presentations and posters across GSK US therapeutic areas: oncology, vaccines, infectious disease, respiratory, immunology, nephrology.
Media library - GSK
WEBSearch and download images and B-roll video for use in the media.
Congress Presentations - GSK
WEBView congress posters and presentations from GSK oncology to learn about the latest developments in clinical research on GSK oncology products.
WEBThis secured GSK scientific congress presentations site is intended for health professionals attending the congress who are interested in viewing a GSK presentation via a QR code or URL.
Home | GSK
WEBOur purpose. We are a focused biopharma company with strong momentum and big ambitions, to unite science, technology and talent to get ahead of disease together. We aim to positively impact the health of 2.5 billion people by the end of the decade, as a successful, growing company where people can thrive.
GSK unveils latest research advances demonstrating strength of its ...
WEBMay 26, 2022 · GSK will also present findings from its early-stage pipeline assets, including a poster discussion on the AMBER study evaluating cobolimab, an investigational anti-TIM-3 targeting monoclonal antibody, in combination with dostarlimab in patients with advanced or metastatic melanoma (ASCO abstract #9513).